news-med.jpg

Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington's disease

Strategic alliance with CHDI to accelerate development of drugs for Huntington's disease One of the largest strategic drug discovery alliances within Evotec 

Topics: Corporate, Evotec, CHDI, Huntington's disease Read More

Evotec and CENTOGENE sign global strategic partnership on drug discovery projects in rare genetic diseases

Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform  

Topics: Corporate, Evotec, Drug Discovery, CENTOGENE, rare genetic diseases, IPSC Read More

Evotec and Novo Nordisk form strategic research alliance in diabetes and obesity

The alliance builds upon Evotec's leading drug discovery and development capabilities in diabetes and related co-morbidities Novo Nordisk accesses Evotec's integrated discovery and development platform to progress new molecules from concept to IND including Evotec's INDiGO platform

Topics: Corporate, Evotec, Novo Nordisk, diabetes, Obesity, Drug Discovery, Drug Development Read More

Evotec partner Haplogen enters into collaboration with Bayer

Focus on pulmonary diseases with high unmet medical need Integrated Haplogen-Bayer collaboration builds upon pulmonary portfolio created by Evotec and Haplogen Evotec will participate in undisclosed upfront as well as potential milestone and royalty-based payments from Bayer to Haplogen

Topics: Corporate, Evotec, Haplogen, Bayer, pulmonary diseases Read More

Evotec repays 50% of € 140 m acquisition loan

Strong operational cashflow facilitates repayment of € 70 M within the first year of the loan term € 140 M loan was taken to expand Evotec's value chain with Aptuit in August 2017

Topics: Corporate, Evotec, Aptuit Read More

Evotec receives milestone payment for start of Phase II trial in its multi-target alliance with Bayer

Hamburg, Germany, 19 July 2018: Hamburg, Germany, 19 July 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its multi-target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II clinical development ...

Topics: Corporate, Evotec, Bayer, Endometriosis, Chronic cough Read More

Evotec confirm closing of transaction with Sanofi to accelerate infectious disease research and development

Hamburg, Germany, 03 July 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi’s infectious disease unit including licensing-in the majority of Sanofi’s infectious disease research ...

Topics: Corporate, Evotec, Sanofi, infectious diseases Read More

Evotec achieves second milestone in diabetes alliance with Sanofi

Companies are at the forefront of beta cell replacement therapeutic research for diabetes Evotec receives € 3 Million payment from Sanofi Milestone further demonstrates advancement of EVT Innovate initiative “TARGETBCD”

Topics: Corporate, Evotec, Sanofi, TARGETBCD, diabetes, beta cell replacement Read More

Evotec and Sanofi sign definitive agreement to combat infectious diseases

Acceleration of research and development (“R&D”) of novel anti-infectives 100 employees will join Evotec Sanofi will license more than 10 infectious disease (“ID”) R&D assets Sanofi to provide significant support to Evotec including a one-time, upfront payment of € 60 M to support progression of a ...

Topics: Corporate, Evotec, Sanofi, infectious diseases Read More

Evotec forms academic BRIDGE 'LAB591’ with Arix Bioscience and Fred Hutchinson Cancer Research Center

Combination of one of the premier cancer research centers with a strong company builder and Evotec's drug discovery expertise to create and support new companies focused on therapeutic breakthroughs for patients in the areas of oncology and infectious diseases Expands Evotec's academic ‘BRIDGE’ ...

Topics: Corporate, Evotec, Arix Bioscience, Fred Hutchinson Cancer Research Center Read More

Most Read

Posts by Topic